Shareholders' Ordinary and Extraordinary General Meeting dated June 17, 2025 - Median Technologies

We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs.

With eyonis® we are disrupting the management of serious diseases such as lung cancer and liver cancer. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. eyonis® is currently under development.

Imaging Services for Clinical Trials

Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for biopharma sponsors worldwide.

05/09/2025

Notice of Ordinary and Extraordinary General Meeting dated June 17, 2025 (in French only)

05/28/2025

Single voting form for the OEGM dated June 17, 2025 (in French only)

05/28/2025

Management report of the Board of Directors – OEGM dated June 17, 2025

05/28/2025

Text of Resolutions – OEGM dated June 17, 2025

05/28/2025

Management report of the Board of Directors on the consolidated accounts presented according to IFRS standards – OEGM dated June 17, 2025

05/28/2025

Report of the Board of Directors on the Extraordinary decisions – OEGM dated June 17, 2025

05/28/2025

Report of the Board of Directors on the free allocation of shares – OEGM dated June 17, 2025

05/28/2025

Report of the Board of Directors on stock options – OEGM dated June 17, 2025

05/28/2025

Rapport du commissaire aux comptes sur l’émission d’actions et de diverses valeurs mobilières avec maintien et/ou suppression du droit préférentiel de souscription -Résolutions 15 à 22 (in French only)

05/28/2025

Rapport du commissaire aux comptes sur l’émission d’actions et de diverses valeurs mobilières avec suppression du droit préférentiel de souscription – Résolutions 20 et 21 (in French only)

05/28/2025

Rapport du commissaire aux comptes sur l’augmentation du capital réservée aux adhérents d’un plan d’épargne d’entreprise – Résolution 25